Chung-Min Tsai

Chung-Min Tsai

Auto-generated profile, based on publicly available information

Chung-Min Tsai


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
TYTzu-Sen Yang
Tzu-Sen Yang
KOKeng-Liang Ou
Keng-Liang Ou
PPPei-Wen Peng
Pei-Wen Peng
BLBing-Chun Liou
Bing-Chun Liou
WWWei-Ting Wang
Wei-Ting Wang
CSChing-Hua Su
Ching-Hua Su

25 March 2022 in Neurophotonics
Verified
Journal Article
Open access
PDF file
CTChung-Min Tsai
Chung-Min Tsai
SCShwu-Fen Chang
Shwu-Fen Chang
CLChih-Chuan Li
Chih-Chuan Li
HCHsi Chang
Hsi Chang
Treatment of pediatric epilepsy relies on antiepileptic drugs (AEDs), but the response rates to AEDs are ∼72 to 76%.1 New effective and noninvasive treatments for AED-refractory pediatric epilepsy are critically needed. Transcranial photobiomodulation (tPBM) with near-infrared (NIR) light refers to applying NIR transcranially according to the principle of photobiomodulation (PBM, previously termed low-level laser therapy).2 The mechanism of tPBM is based on photon absorption by mitochondrial cytochrome c oxidase (CCO).3 PBM has been studied in neurological diseases for 30 years.4 We recently demonstrated that tPBM (808 nm) attenuates seizures and status epilepticus (SE) induced by pentylenetetrazole (PTZ) in peripubertal rats.5 The behavioral and histopathological results showed that the treatment accomplished this (i) by reducing neuronal damage in the cortex, hippocampus (both GABAergic interneurons and principal cells), thalamus, and hypothalamus; (ii) by protecting hippocampal parvalbumin-positive interneurons—GABAergic interneurons that powerfully inhibit principal cells but are vulnerable to SE-induced apoptosis—from SE-induced apoptosis;6 and (iii) by preserving the integrity of the PV-immunoreactive perisomatic neuronal network surrounding the principal cells.7 Vogel et al.8 further revealed that repetitive tPBM (780 nm) reduced epileptiform discharges in a rat model of stroke-induced epilepsy. Regarding neuroprotection, tPBM has shown effects in reducing neuroinflammatory cytokines,7,9 which along with neuron-specific enolase (NSE) increased in the hippocampus after convulsive status epilepticus (CSE).10,11

3 May 2020 in Journal of Biophotonics
Verified
Journal Article
Open access
PDF file
CTChung‐Min Tsai
Chung‐Min Tsai
SCShwu‐Fen Chang
Shwu‐Fen Chang
HCHsi Chang
Hsi Chang
Convulsive status epilepticus is the most common neurological emergency in children. Transcranial photobiomodulation (tPBM) reverses elevated rodent neurotransmitters after status epilepticus (SE) yet whether tPBM can attenuate seizure behaviors remains unknown. Here, we applied near‐infrared laser at wavelength 808 nm transcranially to peripubertal Sprague‐Dawley rats prior to pentylenetetrazole (PTZ) injection. Hematoxylin‐eosin, immunofluorescence (IF) staining with anti‐parvalbumin (PV) and terminal deoxynucleotidyl transferase dUTP nick‐end labeling (TUNEL) assay after IF staining was performed. Behaviorally, tPBM attenuated the mean seizure score and reduced the incidence of SE and mortality. Histochemically, tPBM reduced dark neurons in the cortex, hippocampus, thalamus and hypothalamus, lessened the apoptotic ratio of parvalbumin‐positive interneurons (PV‐INs) and alleviated the aberrant extent of PV‐positive unstained somata of PCs in the hippocampus. Conclusively, tPBM attenuated PTZ‐induced seizures, SE and mortality in peripubertal rats and reduced PTZ‐induced neuronal injury, apoptosis of PV‐INs and preserved PV positive perisomatic inhibitory network in the hippocampus.

4 April 2019 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
YKYung-Ting Kou
Yung-Ting Kou
HLHui-Tien Liu
Hui-Tien Liu
CHChun-Yin Hou
Chun-Yin Hou
CLChuang-Yu Lin
Chuang-Yu Lin
CTChung-Min Tsai
Chung-Min Tsai
HCHsi Chang
Hsi Chang

21 March 2022 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
CTChung-Min Tsai
Chung-Min Tsai
SCShwu-Fen Chang
Shwu-Fen Chang
HCHsi Chang
Hsi Chang
Background: Convulsive status epilepticus (CSE) prevention is critical for pediatric patients with epilepsy. Immediate intervention before CSE reduce severity. Despite its wide usage as an anticonvulsant, valproic acid (VPA) results in harmful side effects such as dose-dependent hepatotoxicity. Hence, reducing VPA dosage to minimize side effects while maintaining its efficacy is necessary, and transcranial photobiomodulation (tPBM) add-on therapy could facilitate this. We recently demonstrated for the first time that tPBM at a wavelength of 808 nm attenuated CSE in peripubertal rats. However, the effects of VPA with the add-on therapy of tPBM prior to seizures have not yet been explored. This study investigated whether adding tPBM to VPA exerts synergistic effect for CSE prevention in peripubertal rats.Methods: A gallium-aluminum-arsenide laser (wavelength of 808 nm with an exposure duration of 100 s and irradiance of 1.333 W/cm2at the target) was applied transcranially 30 min after VPA injection in Sprague Dawley rats. All the rats received 90 mg/kg of pentylenetetrazole (PTZ). Except for the saline (n = 3), tPBM + saline (n = 3), and PTZ group (n = 6), all the rats received a PTZ injection 30 min after VPA injection. The rats received add-on tPBM with PTZ immediately after tPBM. In the VPA + PTZ group, the rats received low-dose (100 mg/kg,n = 6), medium-dose (200 mg/kg,n = 6), and high-dose (400 mg/kg,n = 7) VPA. In the VPA + tPBM + PTZ group, the rats received low (100 mg/kg,n = 5), medium (200 mg/kg,n = 6), and high (400 mg/kg,n = 3) doses of VPA. Seizures were evaluated according to the revised Racine’s scale in a non-blinded manner.Results: Adding tPBM to low-dose VPA reduced the incidence of severe status epilepticus and significantly delayed the latency to stage 2 seizures. However, adding tPBM to high-dose VPA increased the maximum seizure stage, prolonged the duration of stage 4–7 seizures, and shortened the latency to stage 6 seizures.Conclusions: Adding tPBM to low-dose VPA exerted a synergistic prevention effect on PTZ-induced seizures, whereas adding tPBM to high-dose VPA offset the attenuation effect.

1 March 2019 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
HCHsi Chang
Hsi Chang
CTChung-Min Tsai
Chung-Min Tsai
CHChun-Yin Hou
Chun-Yin Hou
STSung-Hui Tseng
Sung-Hui Tseng
JLJu-Chin Lee
Ju-Chin Lee
MTMin-Lan Tsai
Min-Lan Tsai
To assess the long-term neurodevelopmental outcome of normal-term neonates who were accidentally found to exhibit subependymal pseudocysts (SEPCs), frontal horn cysts, or choroid plexus cysts through cranial ultrasound (CUS) examination in a neonatal health examination. In total, 5569 neonates received CUS examination as an item in a health examination during the first week of birth between 2002 and 2012. Among them, 5147 infants fulfilled the inclusion criteria. The participants were aged between 5 and 15 years at the time when the data were collected. We retrospectively collected these data and interpreted their statistical significance by using one-way analysis of variance, Chi-square test with Yate's correction and odds ratios. The presence of SEPCs was significantly correlated with developmental delay and developmental disability, particularly with attention deficit hyperactivity disorder (ADHD) and autistic spectrum disorder (ASD). The risk of ADHD or ASD was significantly higher in participants with multiple SEPCs, among whom the odds ratios for ADHD and ASD were 6.50 (95% confidence interval [CI] = 2.27-18.64) and 28.54 (95% CI = 5.98-136.36), respectively, higher than those for the total study population. Our data revealed multiple SEPCs in normal-term neonates as a risk factor for neurobehavioral outcome, particularly in ADHD and ASD. Simultaneously, the utility of CUS examination as a health examination item for neonates was confirmed.